MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Nektar Therapeutics Company Profile (NASDAQ:NKTR)

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 1 Sell Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $15.00 (23.76% upside)

Current Analysts' Coverage Summary for Nektar Therapeutics (NASDAQ:NKTR)
Show:
DateFirmActionRatingPrice TargetActions
6/19/2015Roth CapitalReiterated RatingBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2015Piper JaffrayReiterated RatingOverweight$15.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2015Brean CapitalReiterated RatingBuy$17.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015JPMorgan Chase & Co.Lower Price TargetOverweight$19.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015Jefferies GroupLower Price TargetBuy$17.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2014Bank of AmericaReiterated RatingUnderperform$10.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2014Ladenburg ThalmannInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2014MKM PartnersReiterated RatingNeutral$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/27/2013Cowen and CompanyReiterated RatingBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/27/2013William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2013 forward)